Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:INZYNASDAQ:JMACNASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$0.94+11.7%$0.86$0.66▼$3.64$87.28M2.361.52 million shs1.19 million shsINZYInozyme Pharma$3.95+178.2%$1.09$0.72▼$6.24$255.02M1.35741,898 shs49.78 million shsJMACMaxpro Capital Acquisition$4.91-5.6%$6.66$7.50▼$19.22$65.93M0.0174,040 shs3,973 shsPASGPassage Bio$0.30+1.5%$0.37$0.26▼$1.39$18.77M1.68343,754 shs268,519 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+2.56%+6.32%+7.80%-37.79%-76.93%INZYInozyme Pharma+5.19%+14.52%+42.40%+3.65%-69.59%JMACMaxpro Capital Acquisition-5.58%-15.49%-17.41%-27.37%+1,283.10%PASGPassage Bio+11.55%-14.20%-19.40%-46.89%-76.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences2.857 of 5 stars3.53.00.00.01.93.30.6INZYInozyme Pharma3.089 of 5 stars4.43.00.00.02.22.50.0JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio2.187 of 5 stars3.52.00.00.00.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$7.40688.58% UpsideINZYInozyme Pharma 2.75Moderate Buy$11.75197.47% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/APASGPassage Bio 3.00Buy$7.502,383.44% UpsideCurrent Analyst Ratings BreakdownLatest PASG, JMAC, INZY, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/8/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/12/2025INZYInozyme PharmaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$24.00 ➝ $12.003/11/2025INZYInozyme PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $23.003/11/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/11/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.92M8.80N/AN/A$4.17 per share0.23INZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.62N/AN/AN/A-1,290.81%-45.46%-38.07%N/AINZYInozyme Pharma-$71.17M-$1.63N/AN/AN/AN/A-88.42%-57.02%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/APASGPassage Bio-$102.06M-$1.07N/AN/AN/AN/A-72.53%-52.10%N/ALatest PASG, JMAC, INZY, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million3/10/2025Q4 2024CRBUCaribou Biosciences-$0.40-$0.39+$0.01-$0.39$2.11 million$2.08 million3/4/2025Q4 2024PASGPassage Bio-$0.21-$0.20+$0.01-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.387.38INZYInozyme Pharma0.517.687.68JMACMaxpro Capital AcquisitionN/AN/AN/APASGPassage BioN/A5.155.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%INZYInozyme Pharma88.30%JMACMaxpro Capital Acquisition73.18%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.28%INZYInozyme Pharma12.18%JMACMaxpro Capital Acquisition19.27%PASGPassage Bio5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.01 million81.95 millionOptionableINZYInozyme Pharma5064.56 million57.05 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionablePASGPassage Bio13062.15 million59.11 millionOptionablePASG, JMAC, INZY, and CRBU HeadlinesRecent News About These CompaniesPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13 at 5:59 PM | zonebourse.comPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13 at 5:59 PM | zonebourse.comPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13 at 7:00 AM | globenewswire.comPassage Bio (PASG) Expected to Announce Earnings on TuesdayMay 12, 2025 | americanbankingnews.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 SharesApril 18, 2025 | insidertrades.comOrbiMed Advisors vend des actions de Passage Bio pour 49.704$April 18, 2025 | fr.investing.comL’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marchéApril 8, 2025 | fr.investing.comL’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$March 31, 2025 | fr.investing.comL'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$March 14, 2025 | fr.investing.comPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowMarch 7, 2025 | zacks.comPASSAGE BIO, INC. : Chardan Research reste à l'achatMarch 5, 2025 | zonebourse.comL’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$March 5, 2025 | fr.investing.comPassage Bio price target lowered to $6 from $7 at ChardanMarch 5, 2025 | markets.businessinsider.comPassage Bio publie ses résultats du quatrième trimestre et de l'année 2024.March 4, 2025 | zonebourse.comPassage Bio reports FY24 EPS ($1.07) vs ($1.86) last yearMarch 4, 2025 | markets.businessinsider.comPassage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business HighlightsMarch 4, 2025 | globenewswire.comPassage Bio to Participate in Upcoming Investor ConferencesFebruary 26, 2025 | globenewswire.comPassage Bio will again trim workforce in latest cost-cutting moveFebruary 16, 2025 | bizjournals.comLa directrice financière de Passage Bio cède des actions pour 1.685$February 12, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePASG, JMAC, INZY, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$0.94 +0.10 (+11.73%) Closing price 04:00 PM EasternExtended Trading$0.94 0.00 (-0.36%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Inozyme Pharma NASDAQ:INZY$3.95 +2.53 (+178.17%) Closing price 04:00 PM EasternExtended Trading$3.94 -0.01 (-0.13%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Maxpro Capital Acquisition NASDAQ:JMAC$4.91 -0.29 (-5.58%) As of 05/14/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Passage Bio NASDAQ:PASG$0.30 +0.00 (+1.55%) Closing price 04:00 PM EasternExtended Trading$0.29 -0.01 (-3.31%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
